Tobias Schimmelpfennig

Berlin Capital Fund GmbH invests in innovative companies based in the Berlin-Brandenburg region of Germany. The fund focuses on companies operating in the fields of IT, telecommunications, life sciences, media, trade and commercial services.

Scienion AG develops and provides DNA biochips and protein microarrays. It provides its customers in the pharmaceutical, biotech, diagnostic and reagent supply markets, as well as in academic research institutions with products, and services to facilitate confidence and efficiency in aspects of its applications. The company was founded by Holger Eickhoff in 2000 and is headquartered in Dortmund, Germany.

OpenSynergy GmbH develops embedded automotive software solutions. It specializes in core products are the modular software development kit COQOS SDK for cockpit controller and connectivity systems and Bluetooth stack Blue SDK. The company was founded by Andr? Hergenhan, Frank-Peter Boehm, Robert Mitschke, Stefaan Sonck Thiebaut and Rolf Morich in 2007 and is headquartered in Berlin, Germany.

Humedics GmbH operates as a research-based medtech company. It focuses on rapid and precise lover function measurement using LiMax, a breath analysis technology. The company was founded by Martin Stockman, Erwin de Bujizer, and Karsten Heyne in 2009 and is headquartered in Berlin, Germany.

Natural Dental Implants AG provides dental technology products and services. The firm specialized in the development of Replicate, a non-surgical tooth replacement system designed to alternative preserve alveolar bone and adjacent teeth. It offers an alternative solutions to traditional dental implants and three unit dental bridges, with focus on three-dimensional image and impression, natural healing, and temporary and permanent crown features. The company was founded by Ruedger Rubbert and Lea Ellermeier Nesbit in 2009 and is headquartered in Berlin, Germany.

OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany.

Ypsilon 687 GmbH develops solutions for retail technologies. It provides metrics and analytics for evaluations. Its technology allows retail chains, individual shops, restaurants, boutiques, and supermarkets the cost detection and analysis of customers needs. The comapny was founded by Christian Felix Wallin, Robin Henniges, and Kai Grünenwald on July 26, 2013 and is headquartered in Berlin, Germany.

X-on Gesellschaft Für Werbung + Marketing mbH provides advertising agency services. The private company is based in Hannover, Germany. The German company was founded in 2004. The CEO is Stephan Schulze.